# Hemopurifier Plus Pembrolizumab in Head and Neck Cancer

> **NCT04453046** · NA · TERMINATED · sponsor: **Aethlon Medical Inc.** · enrollment: 2 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DEVICE:** Hemopurifier
- **DRUG:** Pembrolizumab 200mg IV

## Key facts

- **NCT ID:** NCT04453046
- **Lead sponsor:** Aethlon Medical Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-22
- **Primary completion:** 2022-11-14
- **Final completion:** 2022-11-14
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Lack of Eligible subjects at study site
- **Last updated:** 2022-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04453046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04453046, "Hemopurifier Plus Pembrolizumab in Head and Neck Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04453046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*